AbbVievsRxSight

ABBV and RXST stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $522B and RxSight (RXST) $220M. Over the last year, with dividends, ABBV moved +30.3% and RXST -46.9%. Dividend yield: ABBV 2.35%, RXST none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    RXST$220M

    ABBV is 2,376 times RXST

  • Revenue, 12 months

    ABBV$66.0B

    RXST$122M

    ABBV is 542 times RXST

  • Net income, 12 months

    ABBV$10.3B

    RXST-$53M

  • Operating margin

    ABBV32.2%

    RXST-50.4%

    82.6 points apart

  • ROIC

    ABBV25.7%

    RXST-18.2%

    43.8 points apart

  • P/E

    ABBV50.7

    RXST–

  • Dividend yield

    ABBV2.4%

    RXST0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    RXST-56.7%

    258.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

RXST-56.7%

20040020222023202420252026
Returns by period
PeriodABBVWith dividendsRXSTWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-46.9%Price -46.9%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%-79.4%-41.0% a yearPrice -79.4%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%-56.7%-15.4% a yearPrice -56.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieRXSTRxSight

Valuation

ABBVRXST
Valuation
Price$295.03$5.32
Market value$522B$220M
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B–0.9
EV/EBIT27.9–
Free cash flow yield3.6%8.5%

Results and growth

ABBVRXST
Results and growth
Revenue, 12 months$66.0B$122M
Net income, 12 months$10.3B-$53M
Free cash flow, 12 months$18.9B$19M
Earnings per share, 12 months$5.81-$1.28
Revenue growth, year on year8.6%-3.9%
Revenue growth a year, past+5.9%over 5 years+55.7%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVRXST
Margins and returns on capital
Gross margin73.7%80.6%
Operating margin32.2%-50.4%
Net margin15.7%-43.8%
ROIC25.7%-18.2%
ROE–-20.0%

Balance sheet

ABBVRXST
Balance sheet
Cash$10.8B$255M
Total debt$80.9B$10M
Net debt / EBITDA3.2–
Interest cover7.1×-4,727.2×

Dividends and buybacks

ABBVRXST
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or RXST

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or RxSight?

By market value, AbbVie ($522B) is about 2,376.2 times RxSight ($220M), at today's prices.

How did ABBV and RXST stock do over the last 5 years?

Since November 12, 2021, ABBV's price moved +152.2% and RXST's -56.7%. With dividends: ABBV +201.5% (+24.7% a year), RXST -56.7% (-15.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or RXST?

The dividend yield at today's price is 2.35% for AbbVie and none for RxSight. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or RxSight?

Over the last twelve months, the net margin was 15.7% for AbbVie and -43.8% for RxSight, and the operating margin 32.2% and -50.4%. Revenue was $66.0B and $122M.

Which is the better investment, AbbVie or RxSight?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.